News | August 06, 2025
Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
Cenexi reports an EBITDA breakeven for the quarter
Cenexi reports an EBITDA breakeven for the quarter
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Subscribe To Our Newsletter & Stay Updated
